Bone Biologics Co. (OTC:BBLG – Get Free Report)’s share price dropped 5.5% during trading on Monday . The stock traded as low as $2.08 and last traded at $2.08. Approximately 39,231 shares changed hands during trading, a decline of 82% from the average daily volume of 222,141 shares. The stock had previously closed at $2.20.
Bone Biologics Trading Down 5.5%
The firm has a market cap of $1.13 million, a price-to-earnings ratio of -0.04 and a beta of 0.66. The company has a 50 day moving average of $3.50 and a 200 day moving average of $4.47.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
See Also
- Five stocks we like better than Bone Biologics
- 5 discounted opportunities for dividend growth investors
- Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4
- Investing In Preferred Stock vs. Common Stock
- Why Datadog Is the AI Infrastructure Firm to Watch Out For
- What Investors Need to Know to Beat the Market
- 4 Stocks Every AI ETF Is Buying—And They’re Not What You Think
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
